Sector News

Mylan throws out Teva bid

April 28, 2015
Life sciences
As expected, Mylan’s board has unanimously and vehemently rejected Teva’s takeover offer of around $40 billion, slamming the proposal for “grossly undervaluing” the firm.
 
Following weeks of speculation, Teva finally made an official, unsolicited move on the firm last week offering $82 per Mylan share in a 50/50 cash/stock transaction.
 
The marriage, Teva said, would create a generics powerhouse with pro forma 2014 annual sales of around $30 billion, though Mylan hasn’t seemed sold on the idea from the start.
 
And today Mylan’s board said Teva’s approach contains nothing that would prompt it to depart from a “successful and longstanding standalone strategy”.
 
Lacking logic
“Teva’s proposal grossly undervalues Mylan, and would require Mylan’s shareholders to accept what we believe are low-quality Teva shares in exchange for their high-quality Mylan shares in a transaction that lacks industrial logic and carries significant global antitrust risk,” noted executive chairman Robert Coury.  
 
In a hard-hitting letter to Teva, Coury said Mylan’s board would not even enter into any discussions regarding an offer unless the starting point was “significantly in excess of $100 per share.”
 
“We also believe that the proposal does not address the serious challenges of integrating two fundamentally different and conflicting cultures under a Teva Board and leadership team with a poor record of delivering sustainable shareholder value,” he said. 
 
Teva responded by saying it remains fully committed to completing the merger.
 
By Selina McKee
 
Source: Pharma Times

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend